Immune checkpoint inhibitors (ICIs) exert robust antitumor activity in non–small-cell lung cancer (NSCLC) without actionable mutations. Apart from isolated case reports, the efficacy of PD-1 blockade ...
Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- ...
Understanding the relationship between obesity and in-hospital outcomes in gastric cancer patients : A nationwide analysis. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results